Form 4 Filing for Atea Pharmaceuticals, Inc. - Polly A. Murphy Stock Transaction
2026-05-20SEC Filing 4 (0001193125-26-232612)
On May 18, 2025, Polly A. Murphy, a director at Atea Pharmaceuticals, Inc. (AVIR), acquired 6,100 shares of common stock through a series of transactions at a weighted average price of $4.1715 per share. The transactions occurred at prices ranging from $4.14 to $4.19 per share. Following this acquisition, Ms. Murphy now holds 92,145 shares of Atea Pharmaceuticals, Inc. common stock. The filing was signed on May 20, 2026, by Andrea Corcoran, as Attorney-in-Fact for Polly A. Murphy.